Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2284
Source ID: NCT00521820
Associated Drug: Pioglitazone
Title: Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure
Acronym:
Status: TERMINATED
Study Results: NO
Results:
Conditions: Diabetes Mellitus
Interventions: DRUG: Pioglitazone|DRUG: Glyburide
Outcome Measures: Primary: Progression of Congestive Heart Failure., At First Event. | Secondary: Change from baseline in Glycosylated Hemoglobin., Weeks 12, 20 and Final Visit.|Change from baseline in Fasting Plasma Glucose., At All Visits.|Change from baseline in Triglycerides., Weeks 8, 16 and Final Visit.|Change from baseline in cholesterol (total cholesterol, high-density lipoprotein and low-density lipoprotein)., Weeks 8, 16 and Final Visit.|Change from baseline in 6 Minute Walking test distance, At Final Visit|Physician & Subject Congestive Heart Failure Global Assessment Score, At Final Visit|Change in New York Heart Association classification, At All Visits.|Minnesota Living with Heart Failure Questionnaire total score., At Final Visit.|Changes in blood pressure and heart rate., At All Visits.|All cause mortality., At First Event.
Sponsor/Collaborators: Sponsor: Takeda
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 518
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2000-06
Completion Date: 2003-10
Results First Posted:
Last Update Posted: 2012-02-28
Locations:
URL: https://clinicaltrials.gov/show/NCT00521820